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Abstract
Background:
International guidelines for hormone-receptor-positive (HRþ), human epidermal growth factor receptor-2
negative (HER2) advanced breast cancer (BC) recommend sequential lines of hormonal therapy (HT), and
only recommend chemotherapy for patients with extensive visceral involvement or rapidly progressive
disease. This study evaluated actual physician-reported treatments for advanced BC in Europe.
Methods:
We conducted a retrospective chart review of 355 postmenopausal women with HRþ, HER2 advanced BC
who progressed on 1 line of HT (adjuvant or advanced) and completed 1 line of chemotherapy
(advanced). Treatment choice was evaluated for each line of therapy.
Results:
Of 355 patients, 111 (31%) received first-line chemotherapy, whereas 218 (61%) and 26 (7%) switched
from HT to chemotherapy in second and third line, respectively. More patients receiving first-line HT had
bone metastases (73% vs 27% chemotherapy). Patients treated with first-line chemotherapy had more brain
(12% vs 3% HT) or extensive liver (13% vs 6% HT) metastases. Subgroup analysis of 188 patients who
received first-line HT and had de novo advanced BC or relapsed/recurrent disease more than 1 year after
adjuvant therapy found that the majority (89%; n¼ 167) of these patients switched to chemotherapy in
second line. However, among these 167 patients, 27% had no significant changes in metastases between
first and second line. Among the 73% of patients who had significant changes in metastases, 20% had no
brain metastases or extensive visceral disease.
Conclusions:
Our study suggests that the guideline-recommended use of multiple HT lines is open to interpretation
and that optimal treatment for European postmenopausal women with HRþ, HER2 advanced BC who
responded to HT may not be achieved.
Introduction
Guidelines for the number of lines of hormonal therapy (HT) that should
be used and when to initiate chemotherapy in patients with hormone-
receptor-positive (HRþ) advanced breast cancer (BC) are not straightfor-
ward1–3. This is due in part to the currently incomplete evidence base for the




















































recommendations, which can make the optimal treatment
strategy open to interpretation. The European guidelines
for the treatment of HRþ, locally recurrent or metastatic
BC recommend multiple, but an indeterminate number of,
HT lines, and without defining HT response3.
Chemotherapy is the recommended treatment when
there is clear evidence of resistance to HT. The inter-
national consensus guidelines for advanced BC concur
with the European guidelines regarding the use of HT as
first choice and as a subsequent option following disease
progression; however, no guidance is provided on the use
of more than two lines of HT or criteria for switching to
chemotherapy2. The National Comprehensive Cancer
Network guidelines recommend continuing HT regimens
as long as clinical benefit was received from the previous
HT regimen, without a clear definition of clinical benefit.
In particular, the duration of stable disease that is clinically
meaningful and implies hormone sensitivity is open
to interpretation. Chemotherapy is recommended only
if there was no clinical benefit from at least three consecu-
tive HT regimens or there is a need for rapid disease
control1. In all three guidelines, chemotherapy is
recommended when there is extensive and/or symptomatic
visceral disease.
In addition to the guidelines for advanced BC, country-
specific differences in access and use of various agents
can influence the treatment regimen that a patient will
receive4. For example, in Europe targeted therapies (e.g.,
bevacizumab and human epidermal growth factor recep-
tor-2 [HER2] antagonists) are more likely to be used
in France than in Germany and least likely to be used in
the United Kingdom5. Furthermore, chemotherapy is
used more frequently in Germany for advanced BC; in
one study, only 48% of patients with HRþ BC were treated
with endocrine therapy irrespective of the number of
metastatic sites or number of organs involved6.
Moreover, wide variation exists in terms of access to
cancer therapies across European countries, with an
emphasis on using generic agents first in countries such
as Germany and most recently in Belgium.
Although evidence-based guidelines do provide some
recommendations for optimal management of advanced
HRþ BC, they may not always be followed or interpreted
consistently by physicians. Understanding the reasons for
differences between ‘real-world’ treatment decisions and
guideline recommendations will enable further guideline
clarification. Furthermore, lack of adherence to the
guideline-recommended treatments may negatively affect
quality of care in patients with BC2,7–9.
This chart review is the first that evaluates actual
physician-reported treatments from adjuvant therapy to
completion of three lines of treatment in the advanced
BC setting for the purpose of providing evidence of HT
and chemotherapy treatment patterns in Europe and
assessing the results against guideline recommendations
in order to highlight issues requiring further clarification.
Methods
Study objective
The objective of the study was to understand the clinical
management and resource utilization of HRþ, HER2-
negative (HER2) advanced BC, with the overall aim of
depicting the treatment decisions as patients progressed
from HT to chemotherapy in the advanced BC setting.
Study design
This was a retrospective chart review performed by phys-
icians or healthcare providers in the areas of gynecology
and medical or clinical oncology who treat advanced BC.
The medical professionals were recruited from five
European countries (Belgium, France, Germany, The
Netherlands, and Sweden) and were selected based on
years of clinical practice after residency or fellowship
(5 and 35 years), proportion of time treating patients
(60%), and the number of patients with breast cancer for
whom they were responsible for systemic treatment deci-
sions in the year prior to the study (50 and 1000
patients). Data from the patient charts were collected
via a questionnaire, and all patient charts remained ano-
nymous. The study was compliant with both European and
individual country regulations.
Chart selection criteria
Postmenopausal patients with HRþ, HER2 advanced BC
diagnosed no earlier than 2008 were reviewed for eligibil-
ity. Advanced BC was defined as metastatic or locally
advanced BC not amenable to curative treatment by
surgery or radiotherapy. Patients (alive or deceased) with
recurring or de novo disease had to have disease progression
with at least one line of HT in the adjuvant or advanced
BC setting (combinations with chemotherapy or targeted
therapy were allowed) and had to have completed at least
two cycles of at least one chemotherapy line in the
advanced BC setting.
Data extraction
Data collected in the questionnaire consisted of patient
demographics and disease characteristics/progression at
the initiation of each treatment line, information on
any/all metastases, and all comorbidities. Maintenance
therapy was treated as a separate line of therapy rather
than being included with the previous treatment.
Treatment details requested for each line included agent,
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dose, duration, and administration route. Data on targeted
therapies (defined as any small-molecule or monoclonal
antibody with a specific mechanism of action) used in
combination with the primary therapy at each line were
also requested. Targeted therapies frequently used to treat
BC at the time of the chart review included bevacizumab,
lapatinib, trastuzumab, and a range of investigational
agents (e.g., poly ADP ribose polymerase, mammalian
target of rapamycin, and tyrosine kinase inhibitors).
In addition, data were collected on each patient’s perform-
ance status. The reasons for switching to the next line
of treatment were also collected.
Statistical analysis
The charts were stratified into three cohorts by key
treatment algorithms based on sequence of HT and
chemotherapy lines, and the information from the
questionnaires was grouped accordingly. Descriptive
statistics were used to summarize the physician and patient
characteristics, treatment details, and decisions.
Results
Evidence base for chart review
Across the five European countries, 952 sites were
approached for physician participation in the chart
review; 94 qualified physicians contributed 399 eligible
patient charts (3–9 charts per physician; Table 1).
The physician locations were evenly distributed across
Europe; however, slightly more charts came from France,
and there was no representation from the Walloon region
of Belgium. The majority of physicians reported a specialty
of medical oncology (62%), whereas 23% reported clinical
oncology and 15% reported gynecology. Most physicians
reported that they treated 50–200 patients with BC in the
year preceding this study, primarily at a teaching hospital
(Figure 1). The majority of participating physicians have
been in clinical practice for 5–10 years.
A total of 355 patient charts representing common
treatment sequences were used in the analysis and placed
into three cohorts: cohort A (n¼ 218) had HT first line,
chemotherapy second line, and any treatment third line;
cohort B (n¼ 26) had HT first and second line with
chemotherapy third line; and cohort C (n¼ 111) had
chemotherapy first line with any treatment second and
third line (Figure 2a). Forty-four patient charts were
excluded from the analysis because they did not meet the
key treatment algorithms established for the majority
of patients who were placed into the three cohorts
(36 patients had only one therapy line in advanced BC
and 8 patients had HT for three treatment lines before
chemotherapy). Overall, there were few differences
across patient cohorts in terms of patient demographics
and characteristics (Table 2). Notably, patients in cohort
C were more likely to have a family history of breast and/or
ovarian cancer and present with liver and/or brain metas-
tases at advanced BC diagnosis. In addition, more patients
in cohort B presented with extensive bone metastases.
Treatment patterns
In the first-line setting, 69% of all patients received HT
(cohorts A and B). There were differences in BC histories
and adjuvant therapies between patients who received
first-line HT (cohorts A and B) and those who received
first-line chemotherapy (cohort C). Of the patients who
received HT first-line, cohort A had the highest propor-
tion of patients with de novo advanced BC and cohort B
had the highest proportion of patients with a later recur-
rence of disease (41 year) after completing adjuvant ther-
apy (Figure 2b). Patients in cohort C (chemotherapy as
first line) had the highest proportion of disease recurrence
during or within 1 year of completing adjuvant therapy.
In addition, cohort C had the highest proportion of
patients who also had received adjuvant chemotherapy
(Figure 2c). Among all patients who received HT in the
first-line setting (n¼ 244; cohorts A and B), the most com-
monly prescribed agent was tamoxifen (29%), followed by
anastrozole (27%), letrozole (23%), exemestane (12%),
and fulvestrant (9%). Among all patients who received
chemotherapy in the first-line setting (n¼ 111; cohort
C), the most commonly prescribed agents were docetaxel
(23%) and paclitaxel (22%), followed by cyclophospha-
mide (19%), epirubicin (18%), and capecitabine (14%).









Gynecologists, %b Charts, n
France 515 64 6 21 0 105
Germany 972 174 76 21 48 79
The Netherlands 774 70 22 19 0 68
Belgium (Flemish region) 71 36 8 17 24 84
Sweden 393 52 15 16 0 63
aPhysicians invited via hospitals and clinics, except in France, where only specialist cancer centers were approached.
bPercentage of participating physicians who were gynecologists.
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The most commonly prescribed targeted agent in the first-
line setting (n¼ 31; cohorts A and C) was bevacizumab
(65%), followed by trastuzumab (28%), lapatinib (2%),
investigational agents (2%), and others (2%).
In the second-line setting, only 22% of all patients
received HT. At the initiation of second-line treatment,
59% of all patients (n¼ 212) had a change in the extent or
location of metastatic sites, mainly involving bone (63%),
liver (54%), and lung (46%). Treatment choice changed
in the second line compared with the first line; there was
no preferred HT agent, and capecitabine (30%) became
the most commonly prescribed chemotherapy agent.
The distribution of targeted agents remained similar.
At the initiation of third-line treatment, 30% of all
patients receivedHT (Figure 2a). The distribution of treat-
ment was similar to that observed in the second-line set-
ting, although 50% of all patients (n¼ 71) had a change in
the extent or location of metastatic sites, mainly involving
bone (70%), liver (63%), and lung (51%). The treatment
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Figure 1. Overview of participating physicians by (a) type of medical institution, (b) years of clinical practice, and (c) number of patients with breast cancer
treated in the past year.
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Figure 2. Patient cohorts by (a) treatment received by line in advanced breast cancer setting, (b) breast cancer history, and (c) adjuvant therapies received. A
subset of patients with recurrent breast cancer did not receive pharmacologic intervention in the adjuvant setting. Adj, adjuvant; CT, chemotherapy; HT,
hormonal therapy; TT, targeted therapy; Tx, therapy.
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with letrozole (27%), exemestane (25%), and fulvestrant
(23%) preferred over tamoxifen (15%) and anastrozole
(13%). The patterns for chemotherapy and targeted
agents remained similar to those at second line. Patient
performance status deteriorated with increasing lines of
therapy, but was not strongly correlated with the transition
from HT to chemotherapy (Figure 3).
Treatment switch rationale
For patients who remained on HT for second-line treat-
ment, physicians reported the absence of life-threatening
metastases and slow speed of disease progression as the
main reasons for this treatment choice (Figure 4a).
Physicians reported rapid disease progression as the main
reason for switching fromHT to chemotherapy for second-
line treatment (Figure 4b). Additionally, among patients
switching from chemotherapy to HT for later lines of treat-
ment, patients’ requirement for a break from chemother-
apy was an increasingly important reason for the switch.
Differences between guideline-recommended
and reported treatments
In general, the majority of patients who received HT and
chemotherapy as their first-line treatment were
appropriately treated according to international guide-
lines. A few patients who received HT first-line had dis-
ease recurrence and extensive liver and/or brain metastases
(n¼ 5) during or within 1 year of completing adjuvant
treatments and were, therefore, eligible for first-line
chemotherapy. Only four patients who received chemo-
therapy first line had limited bone-only metastases and
BC recurrence more than 1 year after completing adjuvant
therapy and thus were eligible for first-line HT.
A larger subgroup of patients who were eligible for
and received HT as first-line treatment according to inter-
national guidelines (de novo advanced BC or advanced BC
recurrence more than 1 year after completing adjuvant
therapy) were also analyzed (n¼ 188). Most (89%;
n¼ 167) of these patients were switched to chemotherapy
in second line. However, 27% (n¼ 45) had no significant
changes in metastases between first- and second-line treat-
ment, and the mean duration of first-line therapy was 9.5
months. Furthermore, among the 122 patients (73%) who
had significant changes in metastases, 34 had no brain
metastases or extensive visceral disease, and mean dur-
ation of first-line therapy was 8.7 months. All together,
there were 79 patients who guidelines would recommend
remain on HT for second-line treatment (based on the
duration of clinical benefit in first line and absence of
visceral disease), but who actually received chemotherapy
Table 2. Patient demographics and disease characteristics at advanced BC diagnosis.
Cohort Aa (n¼ 218) Cohort Bb (n¼ 26) Cohort Cc (n¼ 111) Overall (n¼ 355)
Median age, years 64 61 61 63
Family history, breast/ovarian cancer, % 16 12 26 19
ECOG performance status, %
0–1 77 100 85 81
2–4 20 0 15 17
Unknown 3 0 0 2
AJCC stage grouping, %
IIIA 19 15 14 17
IIIB 10 0 14 11
IIIC 4 0 8 5
IV 67 85 63 67
Strong PgRþ status, %d 71 73 62 68
Tumor proliferation, %e
Ki-67 status520% 12 8 18 14
Ki-67 status unknown 58 73 36 52
Tumor grade 3, % 46 42 48 46
Metastatic site, %
Brain 3 0 12 6
Lung 33 23 32 32
Liver 28 12 47 32
Bone 54 85 54 56
aCohort A had hormonal therapy first line, chemotherapy second line, and any treatment third line.
bCohort B had hormonal therapy first and second line with chemotherapy third line.
cCohort C had chemotherapy first line with any treatment second and third line.
dMay reflect baseline characteristics before advanced breast cancer diagnosis where biopsy was not conducted at advanced breast cancer
diagnosis. Strength of PgRþ status was defined by physician indication of strongly positive or weakly positive.
eKi-67 and grade 3 categories are not mutually exclusive.
AJCC, American Joint Committee on Cancer; BC, breast cancer; ECOG, Eastern Cooperative Oncology Group; PgRþ, progesterone-receptor-
positive.
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in second line. These 79 patients represent 22% of our
total sample for this chart review (n¼ 355) (Table 3).
Discussion
Guidance for when to use HT versus chemotherapy and
when to switch from HT to chemotherapy is not always
clear and consistent in the treatment recommendations for
advanced HRþHER2 BC1–3. For example, there are vari-
ations in the number of HT lines that can be used before
switching to chemotherapy, the duration of HT before
disease progression (i.e., the duration of disease control
during HT) that constitutes a clinical benefit, and the
definition of disease progression/stabilization versus
response. In this analysis, the reporting physicians repre-
sented the typical treating healthcare providers in each
country, with sufficient clinical experience (based
on years in practice and number of patients treated) to
interpret the guidelines and make a treatment choice.
In general, the physician’s choice of initial first-line HT
or chemotherapy was consistent with guideline recom-
mendations; only a small proportion of patients eligible
for first-line chemotherapy received first-line HT and
vice versa. Although the inclusion criteria for this study
required at least one line of chemotherapy, the overall
proportion of patients receiving first-line chemotherapy
appears high (430%), especially considering the toxicities
associated with chemotherapy and the guidelines state-
ment that visceral metastases are not a contraindication
for HT1,2. A recent review of clinical studies in the
advanced BC setting showed that the average median
overall survival was 31.1 months with first-line HT and
20.7 months in trials assessing first-line chemotherapy,
although patient characteristics were not analyzed to
ascertain the degree of disease burden in these studies10.
Furthermore, compared with HT, the use of chemotherapy
is associated with increases in direct costs and resource
utilization such as monitoring tests, treatments to
manage adverse events, and hospitalizations11.
Physician use of HT versus chemotherapy in second-
line treatment was not as consistent with guideline recom-
mendations. Although the physicians frequently cited
rapid disease progression as the main reason for switching
from HT to chemotherapy, the data for the patient char-
acteristics did not appear to corroborate this decision.
Approximately 50% of the patients in cohort A who
received chemotherapy second line had extensive visceral
metastases or other clinical indicators consistent with
rapid disease progression (e.g., short duration of first-line
therapy or high tumor proliferation status).
The drivers of inconsistency between guideline-recom-
mended and actual use of second-line chemotherapy in
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Figure 3. Change in performance status at the start and end of each treatment line by cohort. Performance status (PS) was reported as Eastern Cooperative
Oncology Group 0–5.
Current Medical Research & Opinion 2014




















































definitions of HT response and rate of disease progression
in guideline recommendations. Possible contributors to
these discrepancies are a lack of clinical evidence and
inconsistencies in the available evidence. For example,
clinical trials contributing to treatment guidelines do
not provide consistent definitions for endpoints regarding
disease progression and recurrence12,13. The time point
at which progression and/or recurrence is detected after
adjuvant therapy to qualify as hormone-refractory disease
differs among clinical trials, with some trials further
delineating the time into primary and secondary resist-
ance14–16. In addition, one study that examined adherence
to BC guidelines over 3 years in a hospital in France found
that nonadherence to treatment recommendations was
more likely with uncommon patient clinical profiles and
in areas where clinical evidence was lacking17,18.
Specifically, if physicians considered the guideline recom-
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Figure 4. Physician-reported reasons for treatment choice of (a) hormonal therapy over chemotherapy and (b) chemotherapy over hormonal therapy at each
line of treatment. (Panel a): Other reasons include patient desire, not hormone refractory, radiotherapy, consolidation, and regression for as long as possible
after recent chemotherapy. (Panel b): Other reasons include patient desire, new metastases or progression during hormonal therapy, triple-negative biopsy or
hormone-negative metastasis, maintenance chemotherapy, and can be combined with targeted therapy.
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evidence showed a doubtful patient outcome, physicians
chose treatment options based on their clinical depart-
ment procedures.
Another emerging factor in the interpretation of guide-
lines is the use of targeted therapies. In this study, targeted
therapies were used more with chemotherapy than with
HT. However, recent evidence suggests that multiple
lines of HT with different endocrine agents and combin-
ations with newer targeted agents provide clinical benefit
in appropriate patients14,19. In the current guidelines,
anti-HER2 agents and the antiangiogenic agent bevacizu-
mab are generally considered targeted therapies; the newer
targeted agents are considered additional therapies to
overcome endocrine resistance1,3. The use of these newer
targeted agents was too sparse to assess in our study and will
need to be reviewed for appropriate initiation in future
analyses.
The limitations of our study primarily stem from the
limitations for a retrospective chart review. In reviewing
chart information, there are limitations to the amount of
available data. For example, missing data that could affect
treatment decisions, such as reported symptoms or updated
HER2 status, could bias the perception of treatment pat-
terns. For example, although the inclusion criteria stated
that only patients with HER2 disease were eligible, a
small proportion of patients received trastuzumab and
lapatinib. These patients could have had confirmed
HER2 primary disease, and HER2-targeted therapies
were subsequently used to treat suspected HER2þ meta-
static disease or because of limited treatment options.
In addition, accurate information on treatment decisions
made in the past may be incorrectly recalled. Also, infor-
mation with which the treating physician is not familiar
(e.g., agents used in the adjuvant setting) may be limited.
This study tried to mitigate these concerns by having
the treating physician complete the questionnaire using
relatively recent patient charts.
Conclusion
Although treatment patterns for advanced BC in Europe
were generally consistent with guideline recommenda-
tions, important discrepancies were identified regarding
definitions of disease progression and HT response in the
treatment of European postmenopausal women with HRþ
HER2 advanced BC who responded to HT. Resolving
these issues could improve disease management. Further
work is needed to standardize the designation of hormone-
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